Tarsus director granted RSUs and options
Goodrich Katherine reported acquisition or exercise transactions in this Form 4 filing.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Goodrich Katherine reported acquisition or exercise transactions in this Form 4 filing.
Tarsus Pharmaceuticals director Katherine Goodrich received new equity awards as part of her non-employee director compensation. She was granted 2,417 restricted stock units, each representing one share of common stock, and stock options for 3,837 shares with a strike price of $64.34. Both the RSUs and options vest in full one year after the June 25, 2026 grant date, contingent on her continued board service.
Insider Trade Summary
Grant/Award: 6,254 shares
Grant/Award
2 txns
Insider
Goodrich Katherine
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 3,837 | $0.00 | $0.00 |
| Grant/Award | Restricted Stock Units | 2,417 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 3,837 options (Direct);
Restricted Stock Units — 2,417 units (Direct)
Footnotes (3)
- F1. Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
- F2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
- F3. RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
Key Figures
RSU grant size: 2,417 units
Stock options granted: 3,837 options
Option exercise price: $64.34 per share
+3 more
6 metrics
RSU grant size
2,417 units
RSUs granted June 25, 2026, one-year cliff vesting
Stock options granted
3,837 options
Annual non-employee director option grant, June 25, 2026
Option exercise price
$64.34 per share
Conversion or exercise price for 3,837 underlying common shares
Vesting period
1 year
Both RSUs and options vest on one-year anniversary of grant
Post-grant RSU holdings
2,417 RSUs
Total RSUs following the reported acquisition transaction
Post-grant option holdings
3,837 options
Total options following the reported acquisition transaction
Key Terms
Restricted Stock Unit ("RSU"), non-employee director, Stock Option (right to buy), annual meeting of stockholders
4 terms
Restricted Stock Unit ("RSU") financial
"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock."
non-employee director financial
"Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders."
Stock Option (right to buy) financial
"Stock Option (right to buy) with a conversion or exercise price of 64.3400."
annual meeting of stockholders financial
"Granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did Tarsus Pharmaceuticals (TARS) director Katherine Goodrich receive?
Director Katherine Goodrich received 2,417 restricted stock units and stock options covering 3,837 shares of Tarsus Pharmaceuticals common stock. These awards are part of her compensation for serving as a non-employee director following the company’s 2026 annual meeting of stockholders.
When do Katherine Goodrich’s new Tarsus Pharmaceuticals equity awards vest?
Both the restricted stock units and stock options granted to Katherine Goodrich vest in full on the one-year anniversary of the June 25, 2026 grant date. Vesting is conditioned on her continuous service as a non-employee director on Tarsus Pharmaceuticals’ board during that period.
What is the exercise price of Katherine Goodrich’s Tarsus Pharmaceuticals stock options?
Katherine Goodrich’s stock options have a conversion or exercise price of $64.34 per share for 3,837 underlying common shares. These options were granted as her annual non-employee director option award at the time of Tarsus Pharmaceuticals’ 2026 annual stockholder meeting.
Are Katherine Goodrich’s Tarsus Pharmaceuticals equity awards open-market purchases or compensation grants?
The reported transactions are compensation-related grants, not open-market purchases. Both the restricted stock units and the 3,837-share stock option award were granted in connection with Katherine Goodrich’s service as a non-employee director at the company’s 2026 annual stockholder meeting.
Does the Form 4 show any stock sales by Katherine Goodrich at Tarsus Pharmaceuticals?
The Form 4 does not report any stock sales by Katherine Goodrich. It only shows two acquisition transactions coded as grants: 2,417 restricted stock units and stock options for 3,837 shares, both awarded as part of her non-employee director compensation package.
AI-generated analysis. How Rhea-AI works. Not financial advice.
